Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury

Objectives Determine the role of apolipoprotein M (ApoM) in anthracycline (Dox) cardiotoxicity. Background ApoM binds the cardioprotective sphingolipid sphingosine-1-phosphate (S1P). Circulating ApoM is inversely associated with mortality in human heart failure (HF). Methods In the Penn HF Study (PHFS), we tested the relationship between ApoM and mortality in a subset with anthracycline-induced cardiomyopathy. We measured ApoM in humans and mice treated with Dox and utilized hepatic ApoM transgenic (ApomTG), ApoM knockout (ApomKO), ApoM knock-in mice with impaired S1P binding, and S1P receptor 3 (S1PR3) knockout mice in Dox cardiotoxicity. We assayed autophagy in left ventricular tissue from anthracycline-induced HF patients versus donor controls. Results ApoM was inversely associated with mortality in PHFS, and Dox reduced circulating ApoM in mice and breast cancer patients. ApomTG mice were protected from Dox-induced cardiac dysfunction and loss of left ventricular mass. ApomTG attenuated Dox-induced impairment in autophagic flux in vivo and accumulation of insoluble p62, which was also observed in the myocardium of patients with anthracycline-induced HF. In vehicle-treated mice, ApoM negatively regulated transcription factor EB (TFEB), a master regulator of autophagy and lysosomal biogenesis. The effect of ApoM on TFEB required both S1P binding and S1PR3. In the presence of Dox, ApoM preserved TFEB and cardiomyocyte lysosomal abundance assessed as lysosomal associated membrane protein 1 positive structures in vivo, while S1P mimetic pretreatment of cardiomyocytes prevented Dox-induced changes in lysosomal pH. Conclusions ApoM attenuates Dox cardiotoxicity via the autophagy-lysosome pathway. The association between ApoM and reduced mortality may be explained by its role in sustaining autophagy. Highlights Circulating ApoM is inversely associated with survival in human anthracycline-induced cardiomyopathy Anthracycline treatment reduces circulating ApoM in humans and mice Increasing ApoM attenuates doxorubicin cardiotoxicity, lysosomal injury and preserves myocardial autophagic flux, but does not impact doxorubicin anti-neoplastic efficacy Autophagic impairment is characteristic of human anthracycline cardiomyopathy

[1]  Chen Zhao,et al.  Targeting the Autophagy-Lysosome Pathway in a Pathophysiologically Relevant Murine Model of Reversible Heart Failure , 2022, JACC. Basic to translational science.

[2]  A. Javaheri,et al.  Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy , 2022, Circulation.

[3]  A. Javaheri,et al.  HDL Composition, Heart Failure, and Its Comorbidities , 2022, Frontiers in Cardiovascular Medicine.

[4]  Chang Liu,et al.  Toll-Like Receptor 2 (TLR2) Knockout Abrogates Diabetic and Obese Phenotypes While Restoring Endothelial Function via Inhibition of NOX1 , 2021, Diabetes.

[5]  E. Rietzschel,et al.  Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction , 2021, JACC. Basic to translational science.

[6]  A. Rosenzweig,et al.  Understanding Heart Failure With Preserved Ejection Fraction in a Diabetic Way , 2021, JACC. Basic to translational science.

[7]  Zhirong Lin,et al.  The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy , 2020, Acta pharmaceutica Sinica. B.

[8]  Junjian Wang,et al.  Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression , 2020, Frontiers in Cell and Developmental Biology.

[9]  D. Rader,et al.  Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure , 2020, Circulation.

[10]  Y. Ishikawa,et al.  Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation , 2020, ESC heart failure.

[11]  Lei Deng,et al.  A population-based study of cardiovascular disease mortality risk in US cancer patients. , 2019, European heart journal.

[12]  A. Ballabio,et al.  TFEB activation in macrophages attenuates postmyocardial infarction ventricular dysfunction independently of ATG5-mediated autophagy. , 2019, JCI insight.

[13]  Y. D. Deng,et al.  Treatment with apolipoprotein A1 protects mice against doxorubicin-induced cardiotoxicity in a scavenger receptor class B, type I-dependent manner. , 2019, American journal of physiology. Heart and circulatory physiology.

[14]  B. Hardaway.  Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes , 2019, Current opinion in cardiology.

[15]  A. Kraja,et al.  Transcription Factor EB Activation Rescues Advanced αB‐Crystallin Mutation‐Induced Cardiomyopathy by Normalizing Desmin Localization , 2019, Journal of the American Heart Association.

[16]  F. Gao,et al.  Ferroptosis as a target for protection against cardiomyopathy , 2019, Proceedings of the National Academy of Sciences.

[17]  Terrie E. Kitchner,et al.  Probing the Virtual Proteome to Identify Novel Disease Biomarkers , 2018, Circulation.

[18]  K. Mani,et al.  Lysosomes Mediate Benefits of Intermittent Fasting in Cardiometabolic Disease: The Janitor Is the Undercover Boss. , 2018, Comprehensive Physiology.

[19]  N. Reichek,et al.  Left Ventricular Mass Change After Anthracycline Chemotherapy , 2018, Circulation. Heart failure.

[20]  S. Bhatia,et al.  Predicting and Preventing Anthracycline-Related Cardiotoxicity. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[21]  A. Shah,et al.  Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy , 2018, Heart.

[22]  F. Girolami,et al.  Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience , 2018, European journal of heart failure.

[23]  D. Mann,et al.  Impaired Protein Quality Control During Left Ventricular Remodeling in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor , 2017, Circulation. Heart failure.

[24]  M. Mcdaniel,et al.  Intermittent fasting preserves beta-cell mass in obesity-induced diabetes via the autophagy-lysosome pathway , 2017, Autophagy.

[25]  S. Swendeman,et al.  An engineered S1P chaperone attenuates hypertension and ischemic injury , 2017, Science Signaling.

[26]  B. Dahlbäck,et al.  HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium , 2017, Lipids in Health and Disease.

[27]  Y. Assaraf,et al.  Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis , 2017, Oncotarget.

[28]  B. Warscheid,et al.  A systems study reveals concurrent activation of AMPK and mTOR by amino acids , 2016, Nature Communications.

[29]  Petra C. Kienesberger,et al.  Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy. , 2016, The Biochemical journal.

[30]  Xu Shi,et al.  Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease , 2016, Circulation.

[31]  Herman I. May,et al.  Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification , 2016, Circulation.

[32]  S. Swendeman,et al.  Impaired endothelial barrier function in apolipoprotein M‐deficient mice is dependent on sphingosine‐1‐phosphate receptor 1 , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  K. Margulies,et al.  Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure , 2016, Circulation.

[34]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[35]  C. Weinheimer,et al.  Regulation of the Transcription Factor EB-PGC1α Axis by Beclin-1 Controls Mitochondrial Quality and Cardiomyocyte Death under Stress , 2015, Molecular and Cellular Biology.

[36]  Randolph P. Martin,et al.  Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. , 2014, Journal of the American College of Cardiology.

[37]  R. Mutharasan,et al.  Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. , 2014, The Journal of clinical investigation.

[38]  S. Spiegel,et al.  Hepatic Apolipoprotein M (ApoM) Overexpression Stimulates Formation of Larger ApoM/Sphingosine 1-Phosphate-enriched Plasma High Density Lipoprotein* , 2013, The Journal of Biological Chemistry.

[39]  R. Kwong,et al.  Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. , 2012, The American journal of cardiology.

[40]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[41]  Randolph P. Martin,et al.  Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab , 2012, Circulation. Cardiovascular imaging.

[42]  A. Hoofnagle,et al.  Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. , 2011, Atherosclerosis.

[43]  B. Dahlbäck,et al.  Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M , 2011, Proceedings of the National Academy of Sciences.

[44]  R. James,et al.  Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. , 2010, Cardiovascular research.

[45]  Julie L Prior,et al.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. , 2009, Blood.

[46]  Liu,et al.  Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway , 2009, Circulation.

[47]  B. Porse,et al.  Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice* , 2008, Journal of Biological Chemistry.

[48]  J. Stypmann,et al.  High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P3 Lysophospholipid Receptor , 2006, Circulation.

[49]  B. Dahlbäck,et al.  Isolation and characterization of human apolipoprotein M-containing lipoproteins Published, JLR Papers in Press, May 8, 2006. , 2006, Journal of Lipid Research.

[50]  R. Weichselbaum,et al.  gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. , 2006, Current cancer drug targets.

[51]  T. Hunter,et al.  Nuclear Translocation of Caspase-3 Is Dependent on Its Proteolytic Activation and Recognition of a Substrate-like Protein(s)* , 2005, Journal of Biological Chemistry.

[52]  R. Proia,et al.  The Sphingosine-1-phosphate Receptors S1P1, S1P2, and S1P3 Function Coordinately during Embryonic Angiogenesis* , 2004, Journal of Biological Chemistry.

[53]  T. Ley,et al.  High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. , 2003, Blood.

[54]  B. Dahlbäck,et al.  A Novel Human Apolipoprotein (apoM)* , 1999, The Journal of Biological Chemistry.

[55]  B. A. French,et al.  Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. , 1997, The Journal of clinical investigation.

[56]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.